C3 Glomerulopathy

Panelists discuss how the recent FDA approval of iptacopan marks a turning point in C3 glomerulopathy (C3G) treatment, with experts anticipating pegcetacoplan as the next likely candidate for approval due to promising phase 3 trial results and its transformative potential in patient outcomes.

Panelists discuss how the evolving availability of FDA-approved medications for C3 glomerulopathy (C3G) is reshaping clinical trial design, patient enrollment, and global access, highlighting both ethical challenges and opportunities for continued research.

Panelists discuss how physicians determine when to escalate from conservative management to complement inhibitor therapy in patients with C3 glomerulopathy (C3G), considering factors like proteinuria levels, hematuria persistence, biopsy activity scores, and the critical need for improved diagnostic capabilities to guide targeted treatment selection.

Panelists discuss how improved understanding of C3 glomerulopathy (C3G) pathobiology has led to multiple clinical trials targeting complement pathways, with considerations for efficacy measurement through proteinuria reduction and kidney biopsies, while emphasizing the importance of vaccination and patient education to manage safety concerns associated with complement inhibitors.

The month in review spotlights renal FDA news and novel research about CKD and social determinants of health in kidney care.

Panelists discuss how educating physicians and patients about C3 glomerulopathy (C3G) presents unique challenges due to its rarity, complexity, and the critical role of renal pathologists in diagnosis while emphasizing the growing importance of understanding the complement system as new targeted therapies emerge.

Panelists discuss how eculizumab initially provides short-term benefits for patients with C3 glomerulopathy (C3G) through C5a inhibition and anti-inflammatory effects but often loses efficacy over time as the disease progresses due to inadequate control at the C3 convertase level, suggesting newer complement-targeting therapies may offer better long-term management than C5 blockade.

Norouzi reflects on significant advances in glomerular disease from Q1 and looks ahead to what the rest of 2025 may have to offer.

Panelists discuss how treatment approaches for C3 glomerulopathy (C3G) have evolved from nonspecific immunosuppression to targeted complement inhibition, with the recent FDA approval of iptacopan marking a significant advancement in disease management.

Panelists discuss how C3 glomerulopathy (C3G) is triggered by factors like infections or pregnancy that activate the alternative pathway in genetically predisposed individuals, presenting with diverse clinical manifestations that often overlap with other glomerular diseases, making diagnosis challenging without kidney biopsy.

Panelists discuss how C3 glomerulopathy (C3G) is triggered by factors like infections or pregnancy that activate the alternative pathway in genetically predisposed individuals, presenting with diverse clinical manifestations that often overlap with other glomerular diseases, making diagnosis challenging without kidney biopsy.

Panelists discuss how C3 glomerulopathy is an ultrarare glomerular disease characterized by alternative pathway complement dysregulation, which can be caused by either genetic defects or acquired abnormalities like antibodies against regulatory proteins.

The FDA accepted an sNDA for pegcetacoplan for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

The March 2025 approval for iptacopan marks the first for C3 glomerulopathy and is based on the APPEAR-C3G trial.

Survey findings highlight pediatric nephrologists’ reluctance to list patients with kidney failure due to C3G or IC-MPGN for kidney transplantation.

Carla Nester, MD, discusses her perspective on the APPEAR-C3G 12-month data from ASN Kidney Week 2024.

The APPEAR-C3G trial’s 12-month data show Novartis’ iptacopan significantly reduced proteinuria in C3G, with sustained renal improvements and stable eGFR.

Carla Nester, MD, provides perspective on the results of the VALIANT trial and how it informs the role of pegcetacoplan in C3G and IC-MPGN .

VALIANT trial data support pegcetacoplan as the first effective therapy for proteinuria, C3c staining, and eGFR stability in C3G and IC-MPGN patients.